NCT02519816Unknown2 期
Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD
daphne brockington1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2016年3月最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- The primary endpoint is failure-free survival (FFS) at 24 weeks
研究概览
简要总结
Phase II multicenter, Canadian only study - open to 25 subjects. Study open to subjects with steroid-refractory or dependent chronic graft vs host disease.
Series of 6 aphereses and 28 re-infusions over 24 weeks. Primary endpoint is FFS at 24 weeks. Primary objective is to measure the efficacy of CARE (Continuous Alloreactive T-Cell depletion and Regulatory T-cell Expansion)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Newly diagnosed chronic GVHD as defined by the National Institutes of Health (NIH) Consensus with no more than 24 weeks of treatment with systemic steroids.
- •Chronic GVHD must be refractory or dependent to standard therapy, defined as (one of the following):
- •Progression on prednisone 7 mg/kg/week for 2 weeks, or
- •Stable disease on ≥ 3.5 mg/kg/week of prednisone for 4-8 weeks, or
- •Inability to taper prednisone below 3.5 mg/kg/week.
排除标准
- •Persistent, recurrent or late-onset acute GVHD, without signs of chronic GVHD.
- •Overlap GVHD syndrome with uncontrolled features of previously diagnosed acute GVHD.
- •Treatment with more than two systemic non-steroidal immunosuppressants within 4 weeks prior to enrollment.
- •Time from allogeneic transplantation > 2 years. OR
- •Lymphocyte count < 0.2 x 109/L on two last consecutive CBCs before inclusion
结局指标
主要结局
The primary endpoint is failure-free survival (FFS) at 24 weeks
时间窗: 24 weeks
次要结局
未报告次要终点
研究者
daphne brockington
Dr. Imran Ahmad
Maisonneuve-Rosemont Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell TransplantAcute Undifferentiated LeukemiaAcute Biphenotypic LeukemiaAcute Leukemia of Ambiguous LineageAllogeneic Hematopoietic Stem Cell Transplantation RecipientBlastic Plasmacytoid Dendritic Cell NeoplasmBlasts Under 25 Percent of Bone Marrow Nucleated CellsBlasts Under 5 Percent of Bone Marrow Nucleated CellsMyelodysplastic Syndrome With Excess Blasts-1Myelodysplastic Syndrome/Acute Myeloid LeukemiaBurkitt LeukemiaChronic Monocytic LeukemiaLymphoblastic LymphomaMyeloproliferative NeoplasmMast Cell LeukemiaAcute LeukemiaAcute Lymphoblastic LeukemiaMixed Phenotype Acute LeukemiaNCT03779854Fred Hutchinson Cancer Center45
Unknown
1 期
A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-DiseaseGraft vs Host DiseaseNCT02385019Instituto de Medicina Molecular João Lobo Antunes22
进行中（未招募）
2 期
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast CaBreast AdenocarcinomaEstrogen Receptor- Negative Breast CancerEstrogen Receptor-positive Breast CancerHER2/Neu NegativeInvasive Breast CarcinomaProgesterone Receptor NegativeProgesterone Receptor Positive TumorStage II Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerTriple-negative Breast CarcinomaNCT02957968Virginia Commonwealth University46
终止
1 期
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and SirolimusGraft Versus Host DiseaseNCT01453140Hackensack Meridian Health3
已完成
2 期
Multicenter phase I/IIa study using T-cell receptor gene therapy in metastatic melanomamaligne melanomauveal melanoma1003005410040900skin cancerNL-OMON47165ederlands Kanker Instituut20